SFA
NVAX icon

Semmax Financial Advisors’s Novavax NVAX Stock Holding History

Semmax Financial Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-366
Closed -$2.99K – 433
2024
Q4 		$2.99K Hold
366
– – ﹤0.01% 276
2024
Q3 		$3.1K Buy
+366
New +$4.73K ﹤0.01% 273

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Semmax Financial Advisors's NVAX Position: Q1 2025 in Review

Semmax Financial Advisors sold out of Novavax (NVAX) in Q1 2025, closing a stake of 366 shares — an estimated $2.99K sold.

Semmax Financial Advisors first reported a position in NVAX in Q3 2024 and held it in 2 quarters. The position peaked at $3.1K in Q3 2024. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Semmax Financial Advisors reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • Semmax Financial Advisors sold 366 Novavax shares in Q1 2025, an estimated $2.99K.
  • Semmax Financial Advisors first reported a position in Novavax in Q3 2024 and held it in 2 quarters.
  • Semmax Financial Advisors's Novavax position peaked at $3.1K in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Semmax Financial Advisors's 13F filing for Q1 2025, filed 16 May 2025.